Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease.
Thayu
Meena
M
Division of Gastroenterology and Nutrition, The Children's Hospital of Philadelphia, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. thayu@email.chop.edu
Markowitz
Jonathan E
JE
Mamula
Petar
P
Russo
Pierre A
PA
Muinos
William I
WI
Baldassano
Robert N
RN
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy; D017809:Fatal Outcome; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D008113:Liver Neoplasms / Q000175:diagnosis / Q000209:etiology*; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000209:etiology*; D015122:Mercaptopurine / Q000009:adverse effects* / Q000627:therapeutic use; D013160:Splenic Neoplasms / Q000175:diagnosis / Q000209:etiology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D015122:Mercaptopurine